News & Updates
Filter by Specialty:
Use of RAS inhibitors associated with lower cancer risk in T2D
03 Oct 2022
byNatalia Reoutova
A real-world study of over 250,000 type 2 diabetes (T2D) patients from Hong Kong has found that use of renin-angiotensin-system inhibitors (RASIs) is independently associated with reduced risk of cancer, including diabetes-related cancers and cancer-specific mortality in diabetes.
Use of RAS inhibitors associated with lower cancer risk in T2D
03 Oct 2022
Brensocatib has no impact on COVID-19 clinical outcomes
02 Oct 2022
byRoshini Claire Anthony
Results of the STOP-COVID trial, presented at ERS 2022, showed no clinical outcome benefit with the dipeptidyl peptidase-1 (DPP-1) inhibitor brensocatib compared with placebo in patients hospitalized with COVID-19 in the UK.
Brensocatib has no impact on COVID-19 clinical outcomes
02 Oct 2022
Treatment-resistant depression imposes high healthcare utilization
02 Oct 2022
Patients suffering from treatment-resistant depression (TRD) have higher healthcare resource utilization (HRU) associated with psychiatric services, reports a recent study.
